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Abstract
Postherpetic neuralgia (PHN) is a complication of herpes zoster that contributes to significant
suffering for many patients. Analgesics, anticonvulsants, antidepressants, topical formulations
and some interventional treatments have all been utilized in treating the neuropathic pain
associated with PHN. Due to the current opioid epidemic, it is more important than ever for
providers to find alternative methods of pain control for patients experiencing chronic pain.
Medications in a variety of classes have shown varying levels of efficacy in providing relief for
PHN patients, and providers should be aware of the evidence supporting the prescription of these
treatments. Evidence supporting the use of gabapentin, pregabalin, amitriptyline, topical
capsaicin, botulinum toxin injection, vitamin B12 supplementation, and interventional treatments
has been reviewed to determine efficacy and assist providers in determining best practice when
prescribing these medications. Safety considerations related to the previously mentioned
medications have also been reviewed as available. Recommendations for use considering the
quality of available evidence have been provided.
Keywords: postherpetic neuralgia, neuropathic pain, anticonvulsants, antidepressants,
topical formulations, interventional therapies, emerging treatments
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Non-Narcotic Treatment for Postherpetic Neuralgia
Herpes zoster (shingles) is an infectious disease that results from reactivation of the
varicella zoster virus (chickenpox) that remains present in the dorsal root ganglion after infection
(Shrestha & Chen, 2018). The reactivated virus travels along a sensory dermatome, resulting in
a maculopapular rash with fluid filled vesicles that lasts for about ten days (Saguil et al., 2017).
There are about one million new occurrences of herpes zoster every year in the United States,
and it is estimated that about 3 in 10 adults will develop herpes zoster in their lifetime (Saguil et
al., 2017). Pain, itching and burning are often experienced along the path of the dermatome prior
to the rash eruption, with some patients experiencing neuropathic pain long after the rash has
resolved (Shrestha & Chen, 2018). Long term neuropathic pain from herpes zoster, better known
as postherpetic neuralgia (PHN), is the most common complication of shingles with higher
incidence occurring in patients over age 50 (Saguil et al., 2017). In this paper, a case report
about a 70 year old woman who developed shingles will be reviewed. Due to the diagnosis of
this patient, as well as her age, she is at high risk of developing PHN, and long term treatment
may need to be considered for neuropathic pain relief.
Current treatments for PHN are wide ranging, include analgesics, anticonvulsants,
antidepressants, topical formulations, interventional treatments and combination treatments, with
new treatments in development as well (Shrestha & Chen, 2018). As with all treatments, there
are risks and benefits to consider when selecting the right plan for any given patient. While
opioid analgesics may be effective in providing pain relief, the number of negative side effects
and long term dependence issues should make them a last resort when considering the need for
chronic pain control. With the availability of so many other options, it is up to providers to be up
to date on the latest evidence that supports the use of these treatments to treat PHN without
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having to resort to the use of opioid analgesics. The purpose of this report is to review currently
recommended or developing treatments for PHN and determine the quality of evidence
supporting their use.
Case Report
History
Patient is a 70 year old Caucasian female that presented complaining of back pain that
began two days ago. She reports the pain is located in her lower back, on the right side. She has
been experiencing the pain off and on over the past two days, but it has been more present than
not. She describes the pain as a burning, itching sensation. It is worse when there is pressure on
it, like when her clothes rub against it or she lays down on that side. She has tried taking over
the counter Tylenol and applying ice to the area which have helped a bit, but the pain continues
to return after treatment. She reports that the pain is worse in the evening after she has been
moving around throughout the day. She describes the severity of the pain as being a six out of
ten on a numeric rating scale of 0-10 for pain.
Past medical history includes hypertension (for which she takes Lisinopril 20 mg PO
daily) and rheumatoid arthritis (Prednisone 5 mg PO PRN). Past surgical history includes a
hysterectomy two years ago, as well as an appendectomy at that time. Patient has no known
allergies, and reports she is up to date on all immunizations except for the shingles vaccine.
Patient’s family history includes heart disease in her mother, she is unaware of any health
conditions her father may have had. Patient is a retired secretary that lives at home with her
husband. She has two children that live in town and a couple of grandsons. She spends her time
gardening and working in her yard when the weather is nice, and sewing during the winter
months. Patient denies any smoking history or tobacco use in any form. She reports drinking
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the occasional glass of wine with dinner, about 2-3 drinks/month. Patient denies the use of any
illegal substances or inappropriate drug use.
Physical Examination
The patient’s blood pressure upon exam was 154/90, pulse was 78 bpm, temperature was
99.1 orally, and oxygen saturation was 96% on room air. Patient reported she was in pain, and
rated her pain a six out of ten. The patient was in no apparent distress, a systolic grade 2 murmur
was noted upon cardiac auscultation and lung sounds were clear to anterior and posterior
auscultation. Examination of the patient’s back revealed a one inch by five inch cluster of
reddened skin with raised, yellow, fluid filled vesicles along the right L3 dermatome. The rash
began midline to the lower spine and extended along the right side of the patient’s back towards
the hip, it did not extend across midline or towards the left at all.
Diagnosis, Treatment and Follow Up
The diagnosis in this case was herpes zoster along the right L3 dermatome. The
symptoms had been present for approximately 48 hours without any complications, making this
patient a good candidate for antiviral treatment. The recommended treatment in this case was
oral Valacyclovir 1000 mg three times daily for one week. The goals of this therapy are to
decrease the length of illness and severity of symptoms associated with herpes zoster (Albrecht,
2018). Antiviral therapy can prevent the development of new herpetic lesions as well as improve
the rate of healing for current lesions (Albrecht, 2018). Transmission of the herpes zoster virus
is possible during infection, and antiviral therapy can help decrease viral shedding to lower the
risk of spreading the disease (Albrecht, 2018). In addition to the above goals, completing this
treatment is meant to prevent the development of postherpetic neuralgia in patients with herpes
zoster (Albrecht, 2018).
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For acute pain and discomfort associated with an uncomplicated herpes zoster infection,
the treatment plan should also include NSAIDS or Tylenol while the patient recovers with the
disease (Albrecht, 2018). In some instances, like with severe or sleep disturbing pain, opioid
pain relief has been considered useful for a short amount of time (Albrecht, 2018). Close patient
monitoring is recommended while patients are treated and as clinical symptoms resolve. It is
recommended that this patient return to clinic at the completion of antiviral therapy, about one
week later, to assess for healing and pain control (Albrecht, 2018). The goal is to be able to
discontinue analgesic treatment of any acute pain associated with shingles. It is also important to
provide patient education on the possible long term complication of PHN to this patient due to
her age.
Literature Review
To begin the literature review on this topic, the PubMed database was first searched for
relevant research due to the inclusion of biomedical and health literature. The PubMed search
was performed using the medical subject headings (MeSH) terms: (a) “postherpetic neuralgia”;
and (b) “treatment.” The medical subject headings were combined with the Boolean connector
“AND” to make sure all topics were included in relevant articles. Additional limits on the search
included articles written within the last 5 years, articles written in English, studies limited to
human subjects, and systematic reviews or meta-analysis articles only in order to obtain the most
current and relevant articles of the highest quality. The search resulted in 33 articles that met the
established criteria. After reviewing the literature, nine articles were found to contain relevant
information for non-opioid treatment of PHN.
Next, the Cochrane Database of Systematic Reviews was searched to find relevant
articles. The previous MeSH terms used in the PubMed search (“postherpetic neuralgia” and
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“treatment”) were also utilized with the Boolean connector “AND” in an advanced search of the
Cochrane library. A limit of articles written after 2015 was also placed on the search. The
results of this literature search yielded fifteen articles. Many of these reviews had been located
in the PubMed database search, the results of this search only identified one additional article to
add to the literature review.
The PubMed and Cochrane database searches resulted in a total of ten relevant articles
for the literature review. Articles with at least moderate-quality evidence were selected for this
review if the researchers in the studies presented this information. Bias within the articles was
also taken in to account to prevent inclusion of too many articles with a high risk of bias. The
selected articles include four meta-analyses (Song et al, 2018; Wang et al., 2018; Wang et al.,
2017; Zhang et al, 2018), five systematic reviews (Derry et al, 2019; Derry et al., 2017; Lin et
al., 2019; Moore et al., 2015; Wiffen et al., 2017), and one systematic review with meta-analysis
(Shackleton et al., 2016). These ten articles review current and emerging non-opioid treatments
for PHN.
Gabapentin
Two studies directly evaluated the use of gabapentin, an anticonvulsant, for the treatment
of PHN. In a meta-analysis of gabapentin efficacy, eleven randomized control trials were
evaluated comparing the use of gabapentin with placebo in reducing pain intensity (Zhang et al.,
2018). All clinical trials were randomized and double-blinded, with parallel and placebo design,
providing high quality evidence to be used for the meta-analysis. All eleven studies showed
positive results for gabapentin over placebo in reducing patient pain intensity by at least 50%
[RR=-1.79, 95% CI= 1.43, 2.25, P<0.00001] (Zhang et al., 2018). The analysis also revealed
that gabapentin led to improved sleep rating scores for patients suffering from PHN (Zhang et
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al., 2018). All studies recognized the downfall of adverse events related to the use of gabapentin,
which included peripheral edema, dizziness and somnolence reported by subjects (Zhang et al.,
2018). Despite these adverse events, subjects found that the significant pain relief outweighed
the adverse effects of gabapentin usage during the study. Three different formulations of
gabapentin were included: an immediate release form, an extended release form, and an extended
release form including enacarbil, a prodrug to gabapentin. Of the three formulations, the
gabapentin with enacarbil provided the best pain relief and improved sleep scores to subjects,
with no notable difference in adverse effects in comparison to the other formulations (Zhang et
al., 2018). Researchers believe that further studies need be done on the long-term safety and
efficacy of gabapentin usage for PHN relief (Zhang et al, 2018). Notable limitations to this
analysis include a lack of diversity in study subjects and a lack of long-term usage results (Zhang
et al., 2018).
A Cochrane systematic review on the use of gabapentin for treatment of neuropathic pain
yielded similar results regarding the relief of pain in patients with PHN (Wiffen et al., 2017).
The review included eight studies focused on subjects with PHN, with an average of 32% of
subjects in these studies reporting at least a 50% reduction of pain severity score [RR=1.69, 95%
CI= 1.43-2.0, P= 0.020] (Wiffen et al., 2017). This review also included evidence of at least
moderate quality, yielding higher reliability in study findings. The Cochrane review endorsed
higher occurrences of adverse effects with gabapentin including gait disturbance in addition to
the previously mentioned adverse effects, but did note that no serious adverse events occurred
with gabapentin use over placebo (Wiffen et al., 2017). An important limitation noted in this
study was the inclusion of some smaller study sizes that may introduce higher levels of bias into
the review (Wiffen et al., 2017).
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Pregabalin
In the evaluation of pregabalin as treatment for postherpetic pain, the other highly utilized
anticonvulsant for this purpose, a meta-analysis and systematic review were used. The metaanalysis of pregabalin use directly analyzed it’s efficacy in providing pain control for patients
with PHN. This analysis reviewed seven studies, and that found more subjects reported at least
50% pain relief with pregabalin than with a placebo treatment [RR=1.15, 95% CI, 1.03, 1.29,
P=0.010] (Wang et al., 2017). Patients in the analyzed studies reported less sleep interference
when taking pregabalin leading to increase sleep quality for PHN patients (Wang et al., 2017).
One negative of pregabalin noted in the study was cost, but current evaluation of the market
recognizes a generic is now available which may make this a more realistic option for some
patients. While two studies in the analysis did not describe their randomization process, the five
remaining studies were performed with low risk of bias, improving the reliability of the results
compared in this analysis (Wang et al., 2017). Adverse effects of pregabalin were not evaluated
in this study, which may be a future area to consider in evaluating the safety of this medication
for treating PHN.
Pregabalin use for neuropathic pain also received a Cochrane systematic review, with
eight studies focused on its use specifically for PHN (Derry et al., 2019). The eight studies were
all randomized control trials comparing pregabalin with placebo, all with parallel designs. While
some studies in the entire systematic review were recognized to have a high risk of bias due to
sample size, the studies included for the use of pregabalin to treat PHN had larger sized studies,
eliminating a higher risk for bias. This review did have studies that evaluated the different
efficacy between 300 mg and 600 mg doses, and found that for patients reporting at least a 50%
reduction in their pain rating, the 600 mg dose was slightly more effective than to 300 mg dose
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[RB=2.7, 95% CI 2.0-3.5 for 600 mg, vs. RB=2.5, 95% CI 1.9-3.4 for 300 mg] (Derry et al.,
2019). The evidence in this review received a moderate quality rating, which indicates the
improvement in pain relief is most likely due to the pregabalin, at whichever dose the patient is
receiving. This review did find that the adverse effects of dizziness and sleepiness were more
common in patients receiving pregabalin instead of placebo, but did not find any significant
difference in severe adverse events between treatment and placebo groups (Derry et al., 2019).
Amitriptyline
There was one Cochrane systematic review that evaluated the efficacy of amitriptyline
for neuropathic pain, the most popular antidepressant utilized in treating PHN. This review
included five studies that compared efficacy of amitriptyline with various other psychoactive
drugs (fluphenazine, lorazepam, desipramine, maprotiline, nortriptyline and fluoxetine) in
addition to placebo (Moore et al., 2015). Some studies included a cross-over design, but all were
actively controlled. Study comparisons between amitriptyline and the other drugs varied in
efficacy, and there was no convincing evidence that supported the efficacy of amitriptyline as
being superior to any other treatment (Moore et al., 2015). Study sizes within this review were
notably small, resulting in increased bias which further limited the low quality evidence
supporting the use of amitriptyline. One notable recommendation about this treatment is that
many guidelines still recognize amitriptyline as the first line of treatment for neuropathic pain,
often at lower doses than recommended for use as an antidepressant (Moore et al., 2015). While
this does contradict the lack of quality evidence provided by this review, the researchers did
acknowledge that providers should continue to use this as a treatment option due to the length of
time patients have reported good outcomes with use, and the fact that there was also no evidence
supporting that amitriptyline had no effect on neuropathic pain (Moore et al., 2015).
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Topical Capsaicin
Topical application of high concentration capsaicin in treating neuropathic pain also
received a Cochrane systematic review, with four studies in the review focused on its use
specifically for PHN. One difficulty noted in this review was for studies to truly be blinded, due
to side effects like redness and burning produced at the application site by any product
containing capsaicin, which were also the most notable adverse events reported in the study for
both treatment groups (Derry et al., 2017). A subject receiving a true placebo would not
experience these side effects, therefore the participants were given a very low dose capsaicin in
some trials to compare with a high concentration dose to allow for more reliability in results.
The results did show that more participants receiving the high concentration capsaicin did report
at least a 50% reduction in pain severity when compared to the low dose capsaicin or
placebo[RR=1.44, 95% CI 1.12, 1.86, P= 0.005] (Derry et al., 2017). One downfall of the
findings in this review was the low percentage of participants that did report pain reduction,
which signifies that while it may be highly effective, it may also only be effective for a small
amount (Derry et al., 2017). While the review did judge the evidence to be of moderate quality,
due to some small sample sizes and lack of true blinding in some studies, the evidence was
downgraded by the reviewers to low quality despite the positive results reported by patients
(Derry et al., 2017).
Botulinum Toxin
The article supporting the use of botulinum toxin in treating PHN was a systematic
review with meta-analysis that looked at efficacy for PHN, but also trigeminal neuralgia. These
two types of neuropathic pain were not differentiated within the review or analysis. Six studies
were reviewed, with only one study found to have a high risk of bias due to having an unclear
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description of their randomization process (Shackleton et al., 2016). All studies found that the
use of botulinum toxin resulted in more pain reduction for participants. Three of the studies
measured pain reduction of at least 50% in participants receiving the botulinum toxin
[RR=2.892, 95% CI 1.726, 4.848, P<0.001], which was 2.9 times more likely to occur with
treatment than with placebo (Shackleton et al., 2016). Since the analysis contained a smaller
amount of articles, reviewers were only able to recommend botulinum toxin treatment be viewed
as moderate evidence for PHN. One positive point mentioned in this review was the lack of
systemic side effects or any adverse events reported by participants, with the only notable side
effect mentioned being injection site pain (Shackleton et al., 2016). However, since there were a
limited amount of studies to review, further studies would have to be performed to truly evaluate
for all possible side effects.
Vitamin B12
One meta-analysis evaluated the efficacy of Vitamin B12 supplementations in reducing
pain associated with PHN. This analysis included four randomized control trials with rather high
reliability due to lack of bias (Wang et al., 2018). The reduction of pain measurement in this
analysis was different than the other articles in this review, with decrease in score using the
numerical rating scale being evaluated. Overall, results for patients receiving the B12
supplementation were positive, show significantly decreased score after supplementation [MD= 4.01, 95% CI -4.7, -3.33, P<0.01] (Wang et al., 2018). With these promising results and low
risk of bias, reviewers deemed Vitamin B12 supplementation to be moderate quality evidence for
PHN treatment (Wang et al., 2018). Of note, there were smaller sample sizes and less studies in
this analysis than others, which may limit how significant of an effect this may result in for all
patients. Also, the study noted that more participants were recruited during the acute herpetic
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neuralgia stage than the postherpetic stages, which may mean that results might not apply as well
to all patients with postherpetic neuralgia (Wang et al., 2018).
Interventional Treatments
One systematic review looked at a number of interventional treatments to treat PHN,
which may be useful after patients have failed to receive relief with typical oral medications or
topical treatments. The interventional treatments reviewed included various nerve injections,
different types of nerve stimulation, spinal cord stimulation, and dorsal root ganglion destruction
(Lin et al., 2019). Due to a variety of different treatments with different measures being
evaluated in this review, the reviewers did not make any specific comparisons between the
treatments. It was noted that a lack of studies for all interventions and high or unclear risk of
bias in most studies may severely limit the applicability of this review (Lin et al., 2019). The
reviewers recommended that procedure invasiveness, cost of treatment and patient safety all be
considered when determining an interventional treatment, as no single treatment was found to be
more effective than another (Lin et al., 2019). Nerve injections with botulinum toxin or
triamcinolone, stellate ganglion nerve block, transcutaneous electrical nerve stimulation, or
peripheral nerve stimulation should be considered as the first interventional treatments to utilize
for PHN (Lin et al., 2019). Paravertebral block or pulsed radiofrequency would be the next line
of treatments to attempt, and spinal cord stimulation may be used for persistent pain. Two
interventional treatments, dorsal root ganglion destruction and intrathecal methylprednisolone
injections, had the highest amount of adverse events and were only recommended as a last resort
treatment to be performed by an expert in these procedures (Lin et al., 2019). The reviewers did
grade their evidence to be of moderate quality with value to be considered in treating PHN, but
should not be used as standard treatments (Lin et al., 2019).
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Treatment Comparisons
Limited studies were available that compared all of the previously mentioned treatments
for PHN with each other, but one meta-analysis did attempt to compare a number of different
treatments. Reviewers conducted an analysis comparing topical therapies, antiepileptics,
analgesics, antipsychotics, antidepressants, anti-dementia drugs, antivirals and magnesium
sulfate, and provided rankings on how each treatment performed on providing pain relief for
PHN (Song et al., 2018). Of the treatments analyzed that were not analgesics, magnesium
sulfate received the highest rank for PHN treatment (Song et al., 2018). It is noted that only one
study in the meta-analysis included this treatment for comparison, and the sample size in the
study was quite small, making this result considerably biased and significantly limited (Song et
al., 2018). The next three highest ranking treatments, in order of efficacy, were antidepressants
(amitriptyline, nortriptyline, TCAs), antiepileptics (gabapentin, pregabalin, divalproex sodium,
carisbamate) and topical therapies (capsaicin, lidocaine), all with sufficient evidence to support
their practical use in treating PHN (Song et al., 2018). This analysis did recognize that not all
treatments within a certain class were equal in their ability to treat PHN, i.e. gabapentin
outperformed carisbamate in the antiepileptic class (Song et al., 2018). Of the topical therapies
mentioned in this analysis, both capsaicin and lidocaine were noted to perform well, but limited
recent evidence supporting the use of lidocaine was found in the entire body literature. Further
review of lidocaine efficacy within the topical treatment class would be recommended to
determine its use as a treatment for PHN. Anti-dementia drugs and antipsychotics were ranked
next, and antivirals (which are typically used as prevention) actually ranked below placebo in
pain reduction for PHN (Song et al., 2018). The last three treatments mentioned do not have a
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lot of evidence in current literature, which does not support their use at this time due to the
number of other treatments available with proven efficacy.
Learning Points
•

Management of PHN can be achieved for many patients without the long term use of
opioid analgesics

•

Gabapentin, pregabalin and amitriptyline can provide significant reduction for many
patients with PHN, and should be considered as first line treatment options

•

Topical use of capsaicin (and possibly lidocaine) can also be useful in treating PHN, and
are considerable options for second line treatment

•

Botulinum toxin injections and other interventional treatments may be of value in treating
refractory pain due to PHN

•

Vitamin B12 supplementation in combination with other treatments may provide
improved pain control for PHN patients
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